Gilead Is UBS's Top Biotechnology Pick, Roden Says

Sept. 10 (Bloomberg) -- Matthew Roden, senior biotechnology analyst at UBS Securities, talks with Bloomberg Industries senior health-care analyst Andrew Berens and Bloomberg First Word health-care journalist Sasha Damouni about the Hepatitis C marketplace including drug development and potential mergers and acquisitions in the space. (Source: Bloomberg)
The Top Three Stocks to Watch in Asia Today
44:54 - In today’s “Stock Exchange,” Bloomberg’s Yvonne Man, Juliette Saly and Zeb Eckert discuss today’s top three stocks to watch in Asia on “First Up.” (Source: Bloomberg)
  • What’s Next for TPP as Talks End With No Deal
  • Are Searchers for MH370 Looking in the Right Area?
  • Breaking Down China’s PMI Data